Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler acquired 45,226 shares of the company’s stock in a transaction on Monday, January 10th. The shares were acquired at an average cost of $4.34 per share, for a total transaction of $196,280.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
AXDX stock opened at $4.10 on Friday. Accelerate Diagnostics, Inc. has a 1-year low of $3.79 and a 1-year high of $15.60. The company’s 50 day moving average is $5.09 and its 200 day moving average is $5.97.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings data on Tuesday, November 9th. The medical research company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.20. The company had revenue of $3.12 million for the quarter, compared to analysts’ expectations of $3.51 million. During the same period last year, the company posted ($0.33) EPS. As a group, sell-side analysts predict that Accelerate Diagnostics, Inc. will post -1.21 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in AXDX. Marshall Wace LLP purchased a new stake in Accelerate Diagnostics in the first quarter worth $318,000. FMR LLC lifted its stake in Accelerate Diagnostics by 16.1% in the first quarter. FMR LLC now owns 857,069 shares of the medical research company’s stock worth $18,016,000 after acquiring an additional 118,620 shares during the period. HighTower Advisors LLC purchased a new stake in Accelerate Diagnostics in the second quarter worth $217,000. State Board of Administration of Florida Retirement System lifted its stake in Accelerate Diagnostics by 18.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 21,111 shares of the medical research company’s stock worth $170,000 after acquiring an additional 3,304 shares during the period. Finally, Birchview Capital LP lifted its stake in Accelerate Diagnostics by 0.9% in the second quarter. Birchview Capital LP now owns 2,232,857 shares of the medical research company’s stock worth $17,957,000 after acquiring an additional 19,531 shares during the period. 68.27% of the stock is owned by institutional investors.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.